Marija Balic
Marija Balic is an expert in Oncology at University of Pittsburgh Medical Center (United States). As of October 2026, ScienceLeadR ranks Marija Balic in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Marija Balic has authored 255 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 7 of them ongoing. SLR score: 985 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Dermatology - Biochemistry - Informatics
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Short Biography
Marija Balic MD, PhD, MBA, is Professor of Medicine at the University of Pittsburgh School of Medicine. She serves as the Co-Director of Women’s Cancer Program at the UPMC Magee Women’s Hospital, Pittsburgh, PA. and Clinical Co- Leader of Women’s Cancer Research Center (WCRC)
Dr. Balic has joined University of Pittsburgh from the Medical University of Graz, where she was Deputy Head of the Department of Oncology, head of the interdisciplinary breast center, head of research unit for translational breast cancer research, head of the clinical trial unit in the Department of Oncology, lead coordinator for clinical studies in the Department of Internal Medicine, and program director for breast cancer.
She is a prolific member of the breast cancer research community with several ongoing projects with funding, over 100 publications, mentorship of graduate students, numerous presentations at scientific symposia and conferences around the globe, and service to committees and boards.
Dr. Balic earned her MD from the Karl-Franzens University of Graz, School of Medicine and her Dr. Sci. Med and MBA from the Medical University of Graz in Austria.
Organizations
Career arc: 2006 - 2026
Number : 255
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 20
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC NCT07332975 — triple negative breast neoplasms, breast neoplasms, neoplasms, breast, therapeutics | N/A | Recruiting | 2026 |
| A Study With NKT5097 for Adults With Advanced Metastatic Solid Tumors NCT07029399 — injections, triple negative breast neoplasms, fulvestrant, estrogens, safety, breast neoplasms, receptors, estrogen, neoplasms, letrozole, tablets, cyclins, neoplasm metastasis, breast, therapeutics | Phase 1 | Recruiting | 2025 |
| ShortStop HER2 12 Months vs 6 Months of HER2 targeted Medications for People With HER2 Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab NCT06876714 — cells, blood, breast neoplasms, neoplasms, magnetic resonance imaging, mammography, drug therapy, breast, echocardiography, specimen handling, therapeutics, tissues, trastuzumab, chemotherapy | Phase 3 | Recruiting | 2025 |
| A Study for CTC Expression and cfDNA RNA Assessment in Metastatic Breast Cancer Patients NCT06833853 — cells, breast neoplasms, neoplasms, breast, rna | N/A | Recruiting | 2026 |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors NCT05896189 — eye, exercise, cancer survivors, memory, short-term, neuronal plasticity, breast neoplasms, neoplasms, multiple chronic conditions, cognitive dysfunction, algorithms, breast, cognition disorders, eye movements, memory, movement, cognitive training | N/A | Active not recruiting | 2024 |
LeadR Networks
Main global connection map